Our Business

Research and Development

Celsus is pursuing the development of a proprietary complex carbohydrate comprising a rare disaccharide sequence that may be prepared by chemical synthesis, genetically modified organism or site selected 6-O-sulfation of dermatan sulfate for medical needs unmet by heparin or its low molecular weight derivatives.

Manufacture and Controls

Celsus is FDA-registered to manufacture active pharmaceutical ingredients (API's) in a drug establishment that has been approved by the USDA to process restricted animal by-products. These API's are manufactured in compliance with current good manufacturing practices (CGMP), an allowable alternative to ISO-certification under the EU Medical Device Directive.

Global Distribution

Celsus dispatches its products to destinations throughout the world for use in the prophylaxis and treatment of thrombo-embolic disorders, cardiac surgery, hemodialysis and other extracorporeal procedures, catheter lock-flush, blood collection and analysis, blood-interacting medical devices, and affinity chromatography. In support of its global strategy, Celsus maintains drug master file credentials with regulatory authorities in Australia, Canada, the European Union, Japan, and the United States.